Characterization of kininogens in human malignant ascites.
Ascites from seven patients with advanced cancer were studied to characterize the kininogens. Immunological quantification of low molecular weight kininogen (L-kininogen) and high molecular weight kininogen (H-kininogen) by rocket immunoelectrophoresis showed values of 42% and 39%, respectively, compared to control plasma. Release of kinin from the ascites samples was assayed on an isolated rat uterus. The total kinin released from the kininogens was 39% of the value in control plasma, while release selectively from H-kininogen amounted to 25% of plasma. This indicates about 30% of the bradykinin in H-kininogen to be released in vivo in ascites, and points to kinins as possible mediators of the increased vascular permeability causing accumulation of ascites. The function of kininogens as cysteine protease inhibitors (CPIs) was assayed as well, indicating that both L- and H-kininogen function as cysteine protease inhibitors in human ascitic fluid. The proteolytic cleavage of H-kininogen in ascites was studied by polyacrylamide gel electrophoresis and subsequent immunoblotting. H-kininogen was extensively cleaved in ascites compared to control plasma, with large amounts present of a degraded form with Mr of 99 kDa. The bands observed compared well with those described in plasma, and are consistent with contact activation taking place in ascites.
Karlsrud
T S
TS
Dept. of Pharmacology, University of Oslo, Norway.
Buø
L
L
Aasen
A O
AO
Johansen
H T
HT
D001202:Ascitic Fluid / Q000378:metabolism*; D001681:Biological Assay; D002846:Chromatography, Affinity; D015853:Cysteine Proteinase Inhibitors / Q000302:isolation & purification; D006801:Humans; D015151:Immunoblotting; D007122:Immunoelectrophoresis; D007704:Kininogens / Q000378:metabolism*; D009369:Neoplasms / Q000378:metabolism*; D010447:Peptide Hydrolases / Q000378:metabolism
D015853:Cysteine Proteinase Inhibitors; D007704:Kininogens; D010447:Peptide Hydrolases